Lung neoplasm
Therapeutic area
Oncology
Rare disease
No
- Definition
- A benign or malignant, primary or metastatic neoplasm involving the lungs. Representative examples of benign neoplasms include adenoma, papilloma, chondroma, and endobronchial lipoma. Representative examples of malignant neoplasms include carcinoma, carcinoid tumor, sarcoma, and lymphoma.
- Genetic basis
- No
- Non-human condition
- No
- Rare disease
- No
- Listing at source
- Listed
- Condition name
- Lung neoplasm
- Therapeutic area
- Oncology
- lung neoplasm
- lung neoplasm
- lung neoplasm (disease)
- lung neoplasms
- lung tumor
- lung tumour
- neoplasm of lung
- neoplasm of the lung
- tumor of lung
- tumor of the lung
- tumour of lung
- tumour of the lung
- lung
- neoplasm, lung
- neoplasm, pulmonary
- neoplasms, lung
- neoplasms, pulmonary
- Severity
- Severe
- Oncology
- Pulmonology
- MONDO ID
- MONDO:0021117
- Parent condition
- MONDO:0005275
Related records
Broader conditions (12)
- Cancer or benign tumor
- Disease
- Disease by body system or component
- Disease by etiologic mechanism
- Human disease
- Lower respiratory tract disorder
- Lung disorder
- Neoplasm
- Neoplasm of thorax
- Neoplastic disease or syndrome
- Respiratory system disorder
- Respiratory tract neoplasm
Narrower conditions (87)
- Acinar lung adenocarcinoma
- Adenosquamous lung carcinoma
- Adult pulmonary Langerhans cell histiocytosis
- Alveoli adenoma
- Asbestos-related lung carcinoma
- Basaloid large cell lung carcinoma
- Bronchogenic carcinoma
- Bronchus adenoma
- Bronchus carcinoma in situ
- Bronchus mucoepidermoid carcinoma
- Classic pulmonary blastoma
- Clear cell-sugar-tumor of the lung
- Combined lung carcinoma
- Combined small cell lung carcinoma
- Endobronchial leiomyoma
- Epithelial predominant pulmonary blastoma
- Fetal lung interstitial tumor
- Fibroma of lung
- Graham-Boyle-Troxell syndrome
- Hamartoma of lung
Trials (5,189)
- -02341066 and PF-00299804 for Advanced Non-Small Cell Lung Cancer
- 'Lung Health Check' Biomarker Study
- 'SOURCE - LUNG' Stereotactic Ablative Radiation Therapy Of UltRaCEntral LUNG Tumours (SOURCE Lung)
- "Impact of a Nursing Intervention in the Management of Oncological Patients With Lung Cancer Under Treatment With Immunotherapy"
- "Red Morphine Drops" for Symptomatic Treatment of Dyspnoea in Lung Cancer
- (Concerto) Study of BLU-451 in Advanced Cancers With EGFR Exon 20 Insertion Mutations
- (HARMONY) Study of BLU-701 in EGFR-mutant NSCLC
- (SYMPHONY) Phase 1/2 Study Targeting EGFR Resistance Mechanisms in NSCLC
- [18F]-AraG for the Detection of T-Cell Activation in Advanced Non-small Cell Lung Cancer Patients Undergoing PD-1/PD-L1-Directed Therapy
- [18F]-AZAFOL AS POSITRON EMISSION TOMOGRAPHY (PET) TRACER in FR Positive Cancer Imaging
- [18F]HX4 PET/CT Imaging for Detection of Hypoxia
- 0822GCC: Phase 2 Study of Efficacy and Safety of Apricoxib/Placebo With Docetaxel or Pemetrexed in Non-Small Cell Lung Cancer
- 10-Propargyl-10-Deazaaminopterin in Treating Patients With Stage IIIB or Stage IV Non-small Cell Lung Cancer
- 111 Indium CHX-A DTPA Trastuzumab (Indium-Herceptin) for Imaging Breast Cancer
- 11C Topotecan PET Imaging
- 11C-Acetate PET/CT Non-FDG-Avid Tumors
- 13-Cis Retinoic Acid With or Without Vitamin E for Prevention of Lung Cancer
- 18F Labeled FAP Targeted Molecular Probe in Early Tumor Diagnosis
- 18F-ASIS PET/CT Imaging of Tissue Factor Expression In Patients With Primary and Metastastic Cancer
- 18F-FAPI PET in Lung Cancer
Approved drugs (1)
- Etoposide
Drugs in development (60)
- Afatinib Phase 2
- Alectinib Phase 2
- Anetumab ravtansine Phase 2
- Axitinib Phase 2
- Belagenpumatucel-L Phase 2
- Bupivacaine Phase 3
- Camrelizumab Phase 2
- Canertinib dihydrochloride Phase 2
- Carboplatin Phase 3
- Catequentinib Phase 3
- Cisplatin Phase 3
- Cyclophosphamide Phase 3
- Docetaxel Phase 3
- Doxorubicin Phase 2
- Durvalumab Phase 3
- Elraglusib Phase 2
- Endostatin, N-terminal-mggshhhhh Phase 3
- Envafolimab Phase 2
- Erlotinib Phase 3
- F19 131I Phase 1
Other linked drugs (2)
- Catequentinib hydrochloride
- Dacomitinib